Browse > Article
http://dx.doi.org/10.4014/jmb.1004.04035

Quantitative Detection of Residual E. coli Host Cell DNA by Real-Time PCR  

Lee, Dong-Hyuck (Department of Biological Sciences, Hannam University)
Bae, Jung-Eun (Department of Biological Sciences, Hannam University)
Lee, Jung-Hee (Department of Biological Sciences, Hannam University)
Shin, Jeong-Sup (Quality Control Unit, Green Cross Corp.)
Kim, In-Seop (Department of Biological Sciences, Hannam University)
Publication Information
Journal of Microbiology and Biotechnology / v.20, no.10, 2010 , pp. 1463-1470 More about this Journal
Abstract
E. coli has long been widely used as a host system for the manufacture of recombinant proteins intended for human therapeutic use. When considering the impurities to be eliminated during the downstream process, residual host cell DNA is a major safety concern. The presence of residual E. coli host cell DNA in the final products is typically determined using a conventional slot blot hybridization assay or total DNA Threshold assay. However, both the former and latter methods are time consuming, expensive, and relatively insensitive. This study thus attempted to develop a more sensitive real-time PCR assay for the specific detection of residual E. coli DNA. This novel method was then compared with the slot blot hybridization assay and total DNA Threshold assay in order to determine its effectiveness and overall capabilities. The novel approach involved the selection of a specific primer pair for amplification of the E. coli 16S rRNA gene in an effort to improve sensitivity, whereas the E. coli host cell DNA quantification took place through the use of SYBR Green I. The detection limit of the real-time PCR assay, under these optimized conditions, was calculated to be 0.042 pg genomic DNA, which was much higher than those of both the slot blot hybridization assay and total DNA Threshold assay, where the detection limits were 2.42 and 3.73 pg genomic DNA, respectively. Hence, the real-time PCR assay can be said to be more reproducible, more accurate, and more precise than either the slot blot hybridization assay or total DNA Threshold assay. The real-time PCR assay may thus be a promising new tool for the quantitative detection and clearance validation of residual E. coli host cell DNA during the manufacturingprocess for recombinant therapeutics.
Keywords
E. coli host cell DNA; real-time PCR; slot blot hybridization assay; total DNA Threshold assay;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 1  (Related Records In Web of Science)
연도 인용수 순위
1 Jeong, H. S., J. H. Shin, Y. N. Park, J. Y. Choi, Y. L. Kim, B. G.. Kim, et al. 2003. Development of real-time RT-PCR for evaluation of JEV clearance during purification of HPV type 16 L1 virus-like particles. Biologicals 31: 223-229.   DOI   ScienceOn
2 Swartz, J. R. 2001. Advances in Escherichia coli production of therapeutic proteins. Curr. Opin. Biotechnol. 12: 195-201.   DOI   ScienceOn
3 Nissom, P. M. 2007. Specific detection of residual CHO host cell DNA by real-time PCR. Biologicals 35: 211-215.   DOI   ScienceOn
4 Rathore, A. S., S. E. Sobacke, T. J. Kocot, D. R. Morgan, R. L. Dufield, and N. M. Mozier. 2003. Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells. J. Pharm. Biomed. Anal. 32: 1199-1211.   DOI   ScienceOn
5 Wang, K. U., Y. J. Guo, S. H. Sun, K. Shi, S. Zhang, K. H. Wang, Y. Zhang, and Z. H. Chen. 2006. 16S rRNA gene probe quantitates residual host cell DNA in pharmaceutical-grade plasmid DNA. Vaccine 24: 2656-2661.   DOI   ScienceOn
6 Rozen, S. and H. Skaletsky. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132: 365-386.
7 Vilalta, A., V. Whitlow, and T. Martin. 2002. Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal. Biochem. 301: 151-153.   DOI   ScienceOn
8 Walsh, G. 2002. Proteins Biochemistry and Biotechnology, pp. 205-206. John Wiley & Sons Ltd, West Sussex, England.
9 Wit, C., C. Fautz, and Y. Xu. 2000. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. Biologicals 28: 137-148.   DOI   ScienceOn
10 Wolf, J. J., L. Wang, and E. Wang. 2007. Application of PCR technology in vaccine product development. Expert Rev. Vaccines 6: 547-558.   DOI   ScienceOn
11 Wolter, T. and A. Richter. 2005. Assay for controlling host-cell impurities in biopharmaceuticals. BioProcess Int. 3: 40-46.
12 Workman, W. E. 1995. Sample preparation and residual DNA analysis of biopharmaceuticals. Pharmacopeia Forum 21: 479- 483.
13 Kung, V. T., P. R. Panfili, E. L. Sheldon, R. S. King, P. A. Nagainis, J. B. Gomez, D. A. Ross, J. Briggs, and R. F. Zuk. 1990. Picogram quantitation of total DNA using DNA-binding proteins in a silicon sensor-based system. Anal. Biochem. 187: 220-227.   DOI   ScienceOn
14 Martins, S. A. M., D. M. F. Prazeres, J. M. S. Cabral, and G. A. Monteiro. 2003. Comparison of real-time polymerase chain reaction and hybridization assays for the detection of Escherichia coli genomic DNA in process samples and pharmaceuticalgrade plasmid DNA products. Anal. Biochem. 322: 127-129.   DOI   ScienceOn
15 Lahijani, M., M. Duhon, E. Lusby, H. Betita, and M. Marquet. 1988. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive PCR and enzyme linked immunosorbent assay. Hum. Gene Ther. 9: 1173-1180.
16 Lee, D. H., H. S. Jeong, T. E. Kim, S. H. Oh, J. Lee, and I. S. Kim. 2008. Real-time RT-PCR for validation of reovirus type 3 safety during the manufacture of mammalian cell culturederived biopharmaceuticals. Kor. J. Microbiol. 44: 228-236.   과학기술학회마을
17 Lovatt, A. 2002. Applications of quantitative PCR in the biosafety and genetic stability assessment of biotechnology products. Rev. Mol. Biotechnol. 82: 279-300.   DOI   ScienceOn
18 Monis, P. T. and S. Giglio. 2006. Nucleic acid amplificationbased techniques for pathogen detection and identification. Infect. Genet. Evol. 6: 2-12.   DOI   ScienceOn
19 CPMP. 1997. Position Statement on DNA and host cell proteins (HCP) impurities - routine testing versus validation studies. Biotechnology Working Party, Committee for Proprietary Medicinal Product, The European Agency for the Evaluation of Medicinal Product, Human Medicines Evaluation Unit, EU.
20 CPMP. 2001. Position statement on the use of tumourigenic cells of human origin for the production of biological and biotechnological medicinal products. Biotechnology Working Party, Committee for Proprietary Medicinal Product, The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicinal Products for Human Use, EU.
21 FDA. 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, U.S.A.
22 FDA. 2001. Guidance for industry, bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Veterinary Medicine, U.S.A.
23 ICH. 1996. Q2B Validation of analytical procedures: Methodology (guidance for industry). International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
24 Jana, S. and J. K. Deb. 2005. Strategies for efficient production of heterologous proteins in Escherichia coli. Appl. Microbiol. Biotechnol. 67: 289-298.   DOI   ScienceOn
25 Kubista, M., J. M. Andrade, M. Bengtsson, A. Forootan, J. Jonák, K. Lind, et al. 2006. The real-time polymerase chain reaction. Mol. Aspects Med. 27: 95-125.   DOI   ScienceOn
26 Brosius, J., T. J. Dull, D. D. Sleeter, and H. F. Noller. 1981. Gene organization and primary structure of a ribosomal RNA operon from Escherichia coli. J. Bacteriol. 62: 293-300.
27 Banexy, F. 1999. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 10: 411-421.   DOI   ScienceOn